Inhibrx Biosciences, Inc. (INBX)
NASDAQ: INBX · Real-Time Price · USD
91.22
-1.99 (-2.13%)
Jul 15, 2026, 4:00 PM EDT - Market closed
Inhibrx Biosciences Revenue
In the year 2025, Inhibrx Biosciences had annual revenue of $1.30M with 550.00% growth.
Revenue (ttm)
$1.30M
Revenue Growth
+550.00%
P/S Ratio
1,029.47
Revenue / Employee
$11,818
Employees
110
Market Cap
1.34B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.30M | 1.10M | 550.00% |
| Dec 31, 2024 | 200.00K | -1.60M | -88.89% |
| Dec 31, 2023 | 1.80M | -392.00K | -17.88% |
| Dec 31, 2022 | 2.19M | -5.04M | -69.69% |
| Dec 31, 2021 | 7.23M | -5.66M | -43.89% |
| Dec 31, 2020 | 12.89M | -323.00K | -2.44% |
| Dec 31, 2019 | 13.21M | 4.62M | 53.71% |
| Dec 31, 2018 | 8.60M | 204.00K | 2.43% |
| Dec 31, 2017 | 8.39M | 1.72M | 25.86% |
| Dec 31, 2016 | 6.67M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Ardelyx | 427.68M |
| MannKind | 360.78M |
| Wave Life Sciences | 71.80M |
| Immatics | 43.00M |
| Capricor Therapeutics | 11.13M |
| Aktis Oncology | 8.28M |
INBX News
- 4 weeks ago - Inhibrx announces FDA acceptance of BLA for ozekibart - TheFly
- 4 weeks ago - Inhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Patients with Conventional Chondrosarcoma - PRNewsWire
- 2 months ago - Inhibrx price target raised to $325 from $300 at Stifel - TheFly
- 2 months ago - Inhibrx Reports First Quarter 2026 Financial Results - PRNewsWire
- 2 months ago - Inhibrx Biosciences Quarterly report: Q1 2026 - Filings
- 2 months ago - Inhibrx’s INBRX-106 shows potential benefit in HNSCC - TheFly
- 2 months ago - Inhibrx Biosciences Transcript: Study update - Transcripts
- 2 months ago - Inhibrx Biosciences Press release: Study update - Filings